Compare TIC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | DNLI |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2017 |
| Metric | TIC | DNLI |
|---|---|---|
| Price | $11.45 | $17.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $14.63 | ★ $31.58 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,070,000.00 | N/A |
| Revenue This Year | $41.97 | N/A |
| Revenue Next Year | $42.94 | $3,973.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $8.76 | $10.57 |
| 52 Week High | $14.94 | $24.35 |
| Indicator | TIC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 54.81 |
| Support Level | $11.04 | $17.88 |
| Resistance Level | $11.70 | $17.95 |
| Average True Range (ATR) | 0.53 | 0.85 |
| MACD | 0.13 | 0.20 |
| Stochastic Oscillator | 81.06 | 68.85 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.